En

En

中文简体

中文繁体

  • Our Company

    Back

    Our Company

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China

    About Company

    Leadership

    Honor

    Brand Culture

    Member Companies

    Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.
  • Our Business

    Back

    Our Business

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Group Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

    Pharmaceutical Manufacturing

    Vaccines

    Medical Devices

    Medical Diagnosis

    Healthcare Services

    Pharmaceutical Distribution And Retail

    Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
  • R&D

    Back

    R&D

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China.

    Global R&D Center

    R&D Pipeline

    Innovation Platform

    Clinical Development

    R&D News

    Guided by innovation and internationalization, the company continuously enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.
  • Sustainability

    Back

    Sustainability

    In pursuit of sustainable development of talents and products is the social responsibility concept of Fosun Pharma.

    Social Responsibility Strategy

    Special Fund For Fosun Pharma Health Care Initiative

    Social Welfare

    CSR News

    Relevant Policies

    ESG And Sustainability Report Download

    Fosun Pharma has incorporated the sustainable development strategy into its overall development, and established a sound sustainable development management system. It has set up a corporate social responsibility management committee and an environmental, social and governance (ESG) committee under the board of directors to promote the sustainable development of the Group. Moreover, a sound communication mechanism between stakeholders has been established to continuously improve their satisfaction, maintain its competitiveness in sustainable development, and lead the development of the industry.
  • Investor Relations

    Back

    Investor Relations

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China.

    Announcements

    Corporate Governance

    Financial Report

    Investor Presentation Materials

    FAQS

    Investor Contact

    Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Group Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
  • News

    Back

    News

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China.

    Press Release

    Member Companies News

    Media Resources

    Media Contact

    Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
  • Careers

    Back

    Careers

    Some top talent with strong entrepreneurship gathers here with us.

    Talent Concept

    Incentives

    Life At Fosun Pharma

    Join Us

    We are looking for people that recognize and practice our cultural values, and can learn fast to create continuous value; possess profound professional knowledge of the industry, a wide vision of different regions, and global-level expertise in a certain field. We will also be committed to cultivating international top talent with outstanding performance and great potential.

Pharmaceutical Manufacturing

In 2023, the revenue of the pharmaceutical manufacturing segment by Fosun Pharma amounted to 30,222 million.

Fosun Pharma focuses on core therapeutic fields such as tumors (solid tumors and hematologic tumors), self-immunity, central nervous system, and chronic diseases (hepatopathy/metabolic diseases/nephropathy) through independent research and development, cooperative development, license-in, and in-depth incubation, emphasizes strengthening small molecules, antibodies/ADC, cell therapy, and RNA core technical platforms, creates an open and global innovative R&D system, actively explores the technical distribution for tumor vaccine, RNA, AI-assisted therapy, etc., and persistently enhances core R&D capabilities and pipeline value, so as to promote the R&D and commercialization of more FIC (First-in-class) and BIC (Best-in-class) products.

By the end of 2023, the company had more than 70 projects for drugs under development, including innovator drugs, biosimilars. In 2023, the company applied for 206 patents in the pharmaceutical manufacturing segment, including 5 US patents and 11 PCT applications, with 74 patents granted.

  • Major products of oncology and immunomodulation

    Major products of oncology and immunomodulation: Han Qu You (Trastuzumab for Injection), Han Li Kang (Rituximab Injection), Doptelet (Avatrombopag Maleate Tablets), Han Si Zhuang (Serplulimab Injection), Ke Sheng (Xihuang Capsules), Han Da Yuan (Adalimumab Injection), Kai Lai Zhi (Epinastine Hydrochloride Capsules), Zhao Hui Xian (Bicalutamide Tablets), Yi Luo Ze/Tu Mei Si (Pemetrexed Disodium for Injection), Akynzeo (Netupitant and Palonosetron Hydrochloride Capsules), Di Kai Mei (Sorafenib Tosylate Tablets), ondansetron, paclitaxel, and oxaliplatin.

    More

  • Major products of metabolism and digestive System

    Major products of metabolism and digestive system: You Li Tong (Febuxostat Tablets), Atomolan (Glutathione Tablets), animal insulin and its preparations, Bei Yi (Potassium Chloride Granules), Ke Yi (New Compound Aloe Capsules), Atomolan (Reduced Glutathione for Injection), Yi Bao (Recombinant Human Erythropoietin for Injection (CHO Cells)), Li Qing (Alfacalcidol Tablets), Wan Su Ping (Glimepiride Tablets), Wan Su Jing (Empagliflozin Tablets), Fan Ke Jia (Lipoic Acid Injection), human insulin and its preparations.

    More

  • Major products of anti-infection

    Major products of anti-infection: Comirnaty (mRNA COVID-19 Vaccine), Jie Bei An (Azvudine Tablets), antimalarial series such as artesunate, non-lyophilized rabies vaccine for human use (VERO Cell), Xi Chang/Bi Li Shu (Cefmetazole Sodium for Injection), Sha Duo Li Ka (Potassium Sodium Pehydroandroandrographolide Succinate for Injection), anti-tuberculosis series, Pai Shu Xi Lin (Piperacillin Sodium and Tazobactam Sodium for Injection), Meicelin (Cefminox Sodium for Injection), daptomycin, Qiang Shu Xi Lin/Qin Shu/Er Ye Qin (Piperacillin Sodium and Sulbactam Sodium for Injection), caspofungin, Heptodin (Lamivudine Tablets), Cravit (Levofloxacin Tablets, Levofloxacin Injection), micafungin, vancomycin, Er Ye Bi (Cefizoxime Sodium for Injection), Si Ke Ni (Azithromycin Capsules), Ka Di (Flucloxacillin Sodium for Injection), and Rui Sai Ning (Clindamycin Hydrochloride Capsules).

    More

  • Major products of central nervous system

    Major products of central nervous system: Qi Wei (Quetiapine Fumarate Tablets), Qi Cheng (Escitalopram Oxalate Tablets), Chang Tuo Ning (Penehyclidine Hydrochloride Injection), Ao De Jin (Deproteinized Calf Blood Injection), and Lorazepam Tablets.

    More

  • Major products of cardiovascular system

    Major products of cardiovascular system: Heparin preparations, Bang Tan (Telmisartan Tablets), Bang Zhi (Pitavastatin Calcium Tablets), Ya Ni An (Amlodipine Besylate Tablets), Ke Yuan (Calcium Dobesilate Capsules), You Di Er (Alprostadil Dried Emulsion for Injection), Xin Xian An (Meglumine Adenosine Cyclophosphate Injection), and Doptelet (Indapamide Tablets).

    More

  • Major products of APIs and intermediates

    Major products of APIs and intermediates: Amino acid series, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride.

    More

Member Companies